Page 81 - Read Online

Page 6 of 7 Lonardo. Metab Target Organ Damage 2024;4:7 https://dx.doi.org/10.20517/mtod.2023.56

DECLARATIONS
Authors’ contributions
The author contributed solely to the article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Amedeo Lonardo is the Editor-in-Chief of the journal Metabolism and Target Organ Damage.
The author has no other conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author 2024.

REFERENCES
1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease.
Mayo Clin Proc 1980;55:434-8. PubMed
2. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986;8:283-98. PubMed
3. Lazarus JV, Mark HE, Anstee QM, et al; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a
consensus statement. Nat Rev Gastroenterol Hepatol 2022;19:60-78. DOI PubMed
4. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol
2014;2:901-10. DOI
5. Lonardo A, Suzuki A. Sexual dimorphism of NAFLD in Adults. Focus on clinical aspects and implications for practice and
translational research. J Clin Med 2020;9:1278. DOI PubMed PMC
6. Stachenfeld NS, Mazure CM. Precision medicine requires understanding how both sex and gender influence health. Cell
2022;185:1619-22. DOI PubMed
7. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a
meta-analysis of observational cohort studies. Gut 2022;71:778-88. DOI
8. Yi M, Peng W, Feng X, et al. Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses. Aliment
Pharmacol Ther 2022;56:1119-30. DOI PubMed
9. Thomas JA, Kendall BJ, Dalais C, Macdonald GA, Thrift AP. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver
disease: a systematic review and meta-analysis. Eur J Cancer 2022;173:250-62. DOI PubMed
10. Polyzos SA, Kang ES, Tsochatzis EA, et al. Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease? The
epidemic of the 21st century in search of the most appropriate name. Metabolism 2020;113:154413. DOI PubMed
11. Lonardo F, Ballouk C. Metabolism and cancer-select topics. Metab Target Organ Damage 2022;2:8. DOI
12. Liu Z, Lin C, Suo C, et al. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism
2022;127:154955. DOI PubMed
13. Wei S, Hao Y, Dong X, et al. The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of
extrahepatic cancer. Front Endocrinol 2023;14:985858. DOI PubMed PMC
14. Yuan X, Wang X, Wu S, et al. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a
cohort in China. Hepatobiliary Surg Nutr 2023;12:671-81. DOI PubMed PMC
15. Chung GE, Yu SJ, Yoo JJ, et al. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with
metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects. Cancer
Commun 2023;43:863-76. DOI PubMed PMC
16. Crudele L, De Matteis C, Graziano G, et al. AST/ALT-to-platelet ratio (AARPRI) predicts gynaecological cancers: a 8-years follow-up
study in 653 women. Sci Rep 2023;13:17793. DOI PubMed PMC